A phase 2 study of VE-202 in patients with mild to moderate Ulcerative-colitis
Latest Information Update: 27 Jul 2021
At a glance
- Drugs VE 202 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- 21 Jul 2021 According to a Vedanta Biosciences media release, this trial is expected to begin in the second half of 2021.
- 21 Jul 2021 According to a Vedanta Biosciences media release, company completes $68 million series D financing, proceeds expected to be used primarily to support this trial.
- 07 Jul 2021 New trial record